Allergy Therapeutics (AGY) has announced its 6-month interim results to end-December 2025, in line with the January trading update. 1H26 group revenue of £36.3m (1H25: £34.0m) represented c7% (3% at CER) YoY growth which, in our view, is highly encouraging considering the backdrop of the ongoing transition away from unregistered products in Germany and reflects strong growth in the Group’s existing German-registered product portfolio. While we continue to expect revenue growth, we have revised o ....
